The NHS has approved the first daily pill for treating endometriosis, relugolix combination therapy, aiming to give women more control over their treatment. Affecting 1.5 million women in the UK, endometriosis causes significant pain and fatigue. Although the pill can be taken at home unlike injectable options, it is only available to those who have tried all other treatments. This decision by NICE underscores the complexities of managing endometriosis while also addressing cost-effectiveness and patient choice. The new therapy could alleviate pressure on NHS services and offer a more flexible treatment approach.
Helen Knight, director of medicines evaluation at NICE, stated the new treatment represents "a potential step-change in how we manage endometriosis, putting control back in patients' hands while ensuring value for the taxpayer."
The charity Endometriosis UK emphasized that while the new pill increases options for treatment, it will only assist a relatively small number of women, equivalent to about 1,000 patients annually.
Collection
[
|
...
]